Detalhe da pesquisa
1.
A Novel Selective PKR Inhibitor Restores Cognitive Deficits and Neurodegeneration in Alzheimer Disease Experimental Models.
J Pharmacol Exp Ther;
378(3): 262-275, 2021 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34531308
2.
Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.
Bioorg Med Chem Lett;
29(7): 929-932, 2019 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30773432
3.
Total synthesis of (+)-nankakurines A and B and (±)-5-epi-nankakurine A.
J Org Chem;
75(22): 7519-34, 2010 Nov 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20958075
4.
Data on synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel NURR1/NOT agonist potentially useful for the treatment of Parkinson's disease.
Data Brief;
27: 104057, 2019 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31687426
5.
SAR228810: an antibody for protofibrillar amyloid ß peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
Alzheimers Res Ther;
10(1): 117, 2018 11 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30486882
6.
Use of cocultured cell systems to elucidate chemokine-dependent neuronal/microglial interactions: control of microglial activation.
Methods;
29(4): 345-50, 2003 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12725801
7.
G-CSF therapy of ongoing experimental allergic encephalomyelitis via chemokine- and cytokine-based immune deviation.
J Immunol;
168(4): 2011-9, 2002 Feb 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-11823538